kabutan

ONO PHARMACEUTICAL CO., LTD.(4528) Summary

4528
TSE Prime
ONO PHARMACEUTICAL CO., LTD.
2,349.5
JPY
-61.0
(-2.53%)
Mar 19, 3:30 pm JST
14.71
USD
Mar 19, 2:30 am EDT
Result
PTS
outside of trading hours
2,330
Mar 19, 11:32 pm JST
Summary Chart Historical News Financial Result
PER
16.4
PBR
1.31
Yield
3.40%
Margin Trading Ratio
11.36
Stock Price
Mar 19, 2026
Opening Mar 19, 9:03 am
2,351.0 JPY 14.71 USD
Previous Close Mar 18
2,410.5 JPY 15.19 USD
High Mar 19, 9:03 am
2,396.5 JPY 14.99 USD
Low Mar 19, 9:03 am
2,348.5 JPY 14.69 USD
Volume
6,153,800
Trading Value
0.01T JPY 0.09B USD
VWAP
2353.1 JPY 14.73 USD
Minimum Trading Value
234,950 JPY 1,471 USD
Market Cap
1.17T JPY 7.37B USD
Number of Trades
3,736
Liquidity & Number of Trades
As of Mar 19, 2026
Liquidity
High
1-Year Average
4,201
1-Year High Oct 9, 2025
12,294
Margin Trading
Date Short Interest Long Margin Positions Ratio
Mar 13, 2026 83,800 704,500 8.41
Mar 6, 2026 67,700 690,400 10.20
Feb 27, 2026 68,400 709,200 10.37
Feb 20, 2026 69,700 717,100 10.29
Feb 13, 2026 67,500 700,900 10.38
Company Profile
ONO PHARMACEUTICAL CO., LTD. is a mid-tier pharmaceutical company known for its high ratio of in-house developed products, although many are nearing patent expiration. The company is experiencing growth with its new cancer drug "Opdivo".
Sector
Pharmaceuticals
ONO PHARMACEUTICAL CO., LTD. focuses primarily on prescription pharmaceuticals but also produces over-the-counter medications. The company emphasizes research and development, with a strength in innovative in-house products. It operates internationally through subsidiaries engaged in manufacturing, sales, clinical development, and in-licensing/out-licensing activities. The company has sales subsidiaries in Korea and Taiwan, and subsidiaries for clinical development and licensing activities in the United States and the United Kingdom. ONO has achieved significant success with its pioneering cancer immunotherapy drug "Opdivo". The company has also expanded into healthcare-related products, dental supplies, and digital health fields. ONO actively pursues innovation through acquisitions of pharmaceutical startups. The entire group operates under a single business segment of pharmaceuticals.